A5008235770- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
- Head and Neck Surgical Oncology
- Colorectal and Anal Carcinomas
- Neuroblastoma Research and Treatments
- Lung Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Salivary Gland Tumors Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Frailty in Older Adults
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Myasthenia Gravis and Thymoma
- Nutrition and Health in Aging
- Medical Imaging Techniques and Applications
Centre Antoine Lacassagne
2015-2024
Groupe d'Oncologie Radiothérapie Tête et Cou
2013-2024
Université Côte d'Azur
2017-2023
Observatoire de la Côte d’Azur
2017-2022
UniCancer Group
2021
Universidad Católica Cecilio Acosta
2021
Institut Gustave Roussy
2009-2019
Centre Hospitalier Universitaire de Nice
2019
Freed–Hardeman University
2018
Hôpital Avicenne
2018
Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.In randomized, open-label, phase 3 trial, we assigned, in 2:1 ratio, 361 patients whose disease had progressed within 6 months platinum-based to receive nivolumab (at dose mg per kilogram body weight) every 2 weeks...
The new WHO classification of gastroenteropancreatic (GEP) neuroendocrine tumors (NET) implies that G3 neoplasms with mitotic index >20 and/or Ki67 >20% are carcinomas (NEC), described as poorly differentiated, small or large cell types, by analogy lung NEC. To characterize the subgroup non-small-cell-type GEP and thoracic NET according to their pathological features, response cisplatin overall survival (OS). We reviewed clinical presentation referred our institution for 5 years. Data from...
Regulatory T cells (Treg) and tumor-exosomes are thought to play a role in preventing the rejection of malignant patients bearing nasopharyngeal carcinoma (NPC). Treg recruitment by exosomes derived from NPC cell lines (C15/C17-Exo), isolated patients' plasma (Patient-Exo), CCL20 were tested vitro using Boyden chamber assays vivo xenograft SCID mouse model (n = 5), both presence absence anti-CCL20 monoclonal antibodies (mAb). Impact these (NPC-Exo) on phenotype function was determined...
Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients recurrent or metastatic (R/M) squamous cell carcinoma head and neck (SCCHN) who had experienced progression within 6 months platinum-containing chemotherapy.In randomized, open-label, phase III CheckMate 141 trial, were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks investigator's choice (IC) single-agent...
PURPOSE To assess the efficacy and toxicity of sunitinib monotherapy in palliative squamous cell carcinoma head neck (SCCHN). PATIENTS AND METHODS Thirty-eight patients with SCCHN having evidence progressive disease (PD) were treated 37.5 mg/d given continuously until PD or unacceptable toxicity. The primary end point was rate control, defined as stable (SD) partial response (PR) at 6 to 8 weeks after treatment initiation (two-stage design, Simon). Dynamic contrast-enhanced magnetic...
There is no standard for second-line chemotherapy in poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC) patients. We analyzed the antitumor efficacy of 5-fluorouracil and oxaliplatin (FOLFOX) this population. A single-center retrospective analysis consecutive G3-NEC patients treated with FOLFOX after failure a cisplatinum-based regimen between December 2003 June 2012 was performed. Progression-free survival (PFS), overall (OS), response rate, safety were assessed according to...
Background Response patterns with immune checkpoint inhibitors may be different from those chemotherapy. Therefore, assessment of response to immunotherapy the Evaluation Criteria in Solid Tumors (RECIST), version 1.1, could result premature treatment termination. The randomized, open‐label, phase 3 CheckMate 141 trial (NCT02105636), which evaluated nivolumab recurrent/metastatic squamous cell carcinoma head and neck after platinum therapy, allowed beyond first RECIST‐defined progression...
6002 Background: After promising results from the GORTEC TPEx phase II trial, role of taxane instead 5FU in 1st-line R/M HNSCC chemotherapy (CT) remained to be confirmed by comparing reference EXTREME regimen. Methods: Randomized (1:1), open-label trial. Main inclusion criteria were not suitable for locoregional treatment, age 18-70 years, PS <2, creatinine clearance >60ml/min, prior cisplatin <300 mg/m². Reference regimen (arm A: 6 cycles every 3 weeks (Q3W) 5FU–cisplatin-cetuximab...
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma head and neck (R/M SCCHN) post-platinum therapy. Nivolumab IC as first-line treatment also OS R/M SCCHN who progressed on platinum therapy for locally advanced disease in adjuvant setting 1-year follow-up. present long-term follow-up receiving...
Abstract Background Nasopharyngeal carcinoma (NPC) is a human epithelial malignancy consistently associated with the Epstein-Barr virus. The viral genome contained in nuclei of all malignant cells abundant transcription family microRNAs called BART miRNAs. MicroRNAs are well known intra-cellular regulatory elements gene expression. In addition, they often exported extra-cellular space and sometimes transferred recipient distinct from producer cells. Extra-cellular transport facilitated by...
Survival of metastatic gastroenteropancreatic well-differentiated endocrine carcinoma (GEP WDEC) is not well characterized. We evaluated the long-term outcome and prognostic factors for survival in 118 patients with distant metastases from GEP WDEC. Inclusion criteria were 1) pathological review by a single pathologist according to present WHO criteria, 2) absence previous therapy apart surgery, 3) complete morphological evaluation within 3 months including somatostatin receptor...
The purpose of this prospective study was to compare the performance (111)In-octreotide somatostatin receptor scintigraphy (SRS) and (18)fluorodesoxyglucose positron emission tomography (FDG-PET) in aggressive well-differentiated endocrine carcinoma (WDEC) defined by a high Ki67 (≥10%).Eighteen consecutive patients explored single hospital between November 2003 2008 for (≥10%) WDEC were prospectively included. sporadic 17 cases secreting 16 cases. FDG-PET, SRS, computed (CT) performed within...